Details are missing, but Anavex's poster presentation at the Alzheimer's Association International Conference is promising:

Study of the Mechanism of Action of Blarcamesine (Anavex 2-73): Whole Blood Transcriptomics Analysis (RNAseq) Identifies Treatment Impact on Compensatory Pathways by Restoring Key Neurodegenerative Pathways Functionality, including Alzheimer's and Parkinson's Disease Pathway

Now if one of those pathways that is restored is the phosphatidylinositol 3-kinase/Akt pathway, then this drug candidate will change the course of the treatment of Alzheimer's and Parkinson's Disease.  For it is this pathway that leads to the regeneration of neurons, synapses, and axons in the hippocampus, maintains blood flow in the brain, and limits the death of neurons.

https://79bcf7a1-8b8e-483b-b7cf-f5c5192a6d63.usrfiles.com/ugd/79bcf7_c5813c517d9f4ca5aacbeb719508827a.pdf